{
 "name": "台寶生醫",
 "slug": "tw-6892",
 "aliases": [
  "台寶生醫股份有限公司",
  "TWB",
  "6892"
 ],
 "ticker": "6892",
 "industry": "生技醫療業",
 "website": "http://www.twbio-thera.com",
 "summary": "台寶生醫（6892）是興櫃的生技醫療類股公司，2014 年成立，2022 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "台寶生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "TWB",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2022-05-13",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2014-07-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "郭旭崧",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "楊鈞堯",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 940152280,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "安永聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://www.twbio-thera.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：TRK-001（自體擴增調節型T細胞／TRACT）",
   "value": "預防腎臟移植排斥反應｜第二期招募中｜台灣、美國",
   "unit": "",
   "as_of": "2026-04-27",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06552169",
   "note": "NCT06552169；as_of為登錄最後更新公布日；Singulera Therapeutics主導、台寶合作。"
  },
  {
   "claim": "催化劑：TRK-001",
   "value": "第二期試驗主要完成（試驗登錄預估）｜2027-12｜已公告",
   "unit": "",
   "as_of": "2026-04-27",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06552169",
   "note": "NCT06552169；primaryCompletionDateStruct=2027-12 ESTIMATED；不是試驗全部完成日期。"
  },
  {
   "claim": "催化劑：TRK-001",
   "value": "第二期收案完成（公司預估）｜2026（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-09-03",
   "source": "https://www.twbio-thera.com/tw/tool-download/investorbriefing/file/11?note=",
   "note": "官網法說清單公布2026-09-03；第7頁預計2026收案完成。與登錄主要完成2027-12為不同事件。"
  },
  {
   "claim": "管線：IBES CAR-Treg alpha4beta7",
   "value": "潰瘍性結腸炎｜規劃2027年進入臨床一期｜未揭露",
   "unit": "",
   "as_of": "2026-09-03",
   "source": "https://www.twbio-thera.com/tw/tool-download/investorbriefing/file/11?note=",
   "note": "第7頁，合作對象梅約醫學中心；未揭露地區不推定。"
  },
  {
   "claim": "催化劑：IBES CAR-Treg alpha4beta7",
   "value": "進入臨床一期（公司預估）｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-09-03",
   "source": "https://www.twbio-thera.com/tw/tool-download/investorbriefing/file/11?note=",
   "note": "第7頁原文「預計2027進入臨床一期」。"
  },
  {
   "claim": "管線：IBES CAR-Treg（標的未揭露）",
   "value": "自體免疫疾病｜規劃2028年進入臨床一期｜未揭露",
   "unit": "",
   "as_of": "2026-09-03",
   "source": "https://www.twbio-thera.com/tw/tool-download/investorbriefing/file/11?note=",
   "note": "第7頁合作梅約；2028全年跨過18個月終點，不列催化劑。"
  },
  {
   "claim": "管線：IBES Tfr（標的未揭露）",
   "value": "紅斑性狼瘡｜規劃2029年進入臨床一期｜未揭露",
   "unit": "",
   "as_of": "2026-09-03",
   "source": "https://www.twbio-thera.com/tw/tool-download/investorbriefing/file/11?note=",
   "note": "第7頁合作哈佛醫學院。"
  },
  {
   "claim": "管線：In vivo Treg",
   "value": "自體免疫疾病｜規劃2030年進入臨床一期｜未揭露",
   "unit": "",
   "as_of": "2026-09-03",
   "source": "https://www.twbio-thera.com/tw/tool-download/investorbriefing/file/11?note=",
   "note": "第7頁合作對象未揭露。"
  },
  {
   "claim": "管線：Chondrochymal（異體間質幹細胞）",
   "value": "退化性關節炎｜TFDA同意執行第三期臨床試驗｜台灣",
   "unit": "",
   "as_of": "2025-06-08",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "發言日期：2025-06-08 12:18:52；主旨：本公司治療退化性關節炎之異體間質幹細胞新藥Chondrochymal獲衛生福利部同意執行三期臨床試驗；僅核准執行，不推定已收案；較舊NCT05027581是二期歷史試驗。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-6892.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}